ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Plozasiran Update On January 17, 2025, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced that the U.S. Food and Drug Administration (FDA) ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Q1 2025 Earnings Call Transcript February 10, 2025 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.39 EPS, expectations were $-0.42. Chris Anzalone: Thanks, Vince.

The outcomes are to be included in an NDA submission, and Cellectar will be ... A Supplemental New Drug Application (sNDA) submission to the FDA for VTAMA cream, 1% is expected to be made by ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported a larger-than-expected loss for Q1 FY2025, with earnings per share (EPS) at -$1.39, missing the forecast of -$0.39. Revenue also fell short ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In an effort to deepen their technological partnership, Russia and India are exploring opportunities for joint development and production of unmanned aerial vehicles (UAVs). This collaboration is ...

In a tale straight out of a Bollywood script, veteran actor Sanjay Dutt found himself at the center of an astonishing real-life drama in 2018. A 62-year-old homemaker from Mumbai, Nisha Patil, a ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...